Adaptimmune Therapeutics (NASDAQ:ADAP) Earns Buy Rating from Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) in a research report issued to clients and investors on Saturday. The brokerage set a "buy" rating on the biotechnology company's stock.

Several other research analysts also recently weighed in on ADAP. Scotiabank cut their target price on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating for the company in a research note on Friday, March 21st. Wells Fargo & Company cut their price objective on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an "equal weight" rating for the company in a research report on Friday, March 21st. Finally, Guggenheim decreased their target price on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating on the stock in a research report on Wednesday, March 26th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $1.83.

Adaptimmune Therapeutics Price Performance

ADAP traded up $0.06 during midday trading on Friday, reaching $0.31. 6,750,772 shares of the company's stock were exchanged, compared to its average volume of 1,765,311. Adaptimmune Therapeutics has a 1-year low of $0.20 and a 1-year high of $1.48. The stock has a market capitalization of $78.46 million, a PE ratio of -1.39 and a beta of 2.85. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. The business's 50-day moving average price is $0.49 and its 200 day moving average price is $0.65.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last issued its quarterly earnings data on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. The company had revenue of $3.22 million for the quarter, compared to analyst estimates of $16.56 million. As a group, equities analysts anticipate that Adaptimmune Therapeutics will post -0.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Adaptimmune Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Invesco Ltd. raised its stake in Adaptimmune Therapeutics by 82.0% during the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company's stock worth $34,000 after purchasing an additional 28,526 shares during the period. Two Sigma Advisers LP boosted its holdings in Adaptimmune Therapeutics by 492.0% in the fourth quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company's stock valued at $38,000 after acquiring an additional 58,787 shares during the last quarter. Two Sigma Investments LP grew its position in Adaptimmune Therapeutics by 33.5% during the fourth quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company's stock valued at $41,000 after acquiring an additional 19,146 shares during the period. Virtu Financial LLC grew its position in Adaptimmune Therapeutics by 21.5% during the fourth quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company's stock valued at $66,000 after acquiring an additional 21,688 shares during the period. Finally, LPL Financial LLC increased its stake in Adaptimmune Therapeutics by 106.5% during the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company's stock worth $99,000 after acquiring an additional 94,623 shares during the last quarter. 31.37% of the stock is currently owned by hedge funds and other institutional investors.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.